[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:bladder-squamous-cell-carcinoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":27,"states":28},"Bladder Squamous Cell Carcinoma",3,[7,15,21],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06041503","Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)",[11],"Phase 2","RECRUITING","2026-08-26T02:15:30.699880Z","2026-05-05T02:43:28.518599Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05756569","Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology",[11],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:29.051565Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT06161532","Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder\u002FUrinary Tract Cancer, Renal Medullary Carcinoma and Penile C...",[11],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:28.172497Z",[],[]]